PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Blood0 citationsOpen Access

Breaking new ground with antibody-drug conjugates in myeloma

View Full Paper
SUSaad Z. UsmaniMemorial Sloan Kettering Cancer Center

Key Points

  • This research explores the role of antibody-drug conjugates in treating myeloma amidst regulatory challenges.
  • Analysis of market trends in antibody-drug conjugates and CAR T-cell therapies.
  • Evaluation of China's impact on global drug launch strategies.
  • Surveying patient demand and regulatory frameworks across various income settings.
  • The myeloma treatment market is experiencing substantial financial growth.
  • China's evolving CAR T-cell industry poses unique challenges for global strategies.
  • Regulatory processes significantly influence the timing and approach of drug launches.

Abstract

capital inflows, and strong patient demand. 4 The market is too large to ignore; however, its growing domestic CAR T-cell industry and opaque regulatory processes make global launch sequencing far less predictable for multinational firms.These features mean China can shape commercial strategies in ways that differ from both high-income and other middle-income settings.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Saad Z. Usmani (2026) studied this question.

synapsesocial.com/papers/69d1fc28a79560c99a0a1ce3https://doi.org/10.1182/blood.2025032443
Ask AI
Helpful
Bookmark
Share
View Full Paper